These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36765473)

  • 1. [Clinical Analysis of Children with High-Risk Acute Promyelocytic Leukemia].
    Gao QL; LE SH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):33-37. PubMed ID: 36765473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of triple-induction regimen including all-trans retinoic acid, arsenic trioxide plus anthracyclines for adults with non-high-risk acute promyelocytic leukemia].
    Ma RJ; Yuan XL; Jiang L; Yang SW; Yang J; Wang Z; Zhang P; Zhang L; Shang BJ; Cheng LN; Zhang Y; Zhu ZM
    Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(30):2387-2391. PubMed ID: 34404132
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
    Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
    Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
    Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
    Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinctive features associated with differentiation syndrome in acute promyelocytic leukemia in patients treated by all-trans retinoic acid and arsenic trioxide.
    Cingelova S; Mikuskova E; Demitrovicova L; Mikudova V; Slobodova A; Spanikova J; Vasickova R; Urban D; Drgona L; Oravcova I
    Leuk Res; 2024 Oct; 145():107567. PubMed ID: 39197329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.
    Zhang L; Zou Y; Chen Y; Guo Y; Yang W; Chen X; Wang S; Liu X; Ruan M; Zhang J; Liu T; Liu F; Qi B; An W; Ren Y; Chang L; Zhu X
    BMC Cancer; 2018 Apr; 18(1):374. PubMed ID: 29615003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Acute promyelocytic leukemia: state-of-the-art management].
    Asou N
    Rinsho Ketsueki; 2018; 59(6):725-734. PubMed ID: 29973452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
    Xu SN; Chen JP; Liu JP; Xia Y
    Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of combination of ATRA, ATO and anthracyclines induction therapy in patients with acute promyelocytic leukemia].
    Ma RJ; Zhu ZM; Yuan XL; Jiang L; Yang SW; Yang J; Guo JM; Zhang L; Lei PC; Wang Z; Zang YZ; Chen YQ; Wang TB; Kong D; Sun K; Zhang Y
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):523-527. PubMed ID: 28655097
    [No Abstract]   [Full Text] [Related]  

  • 10. Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG).
    Asou N; Adachi K; Tamura U; Kanamaru A; Kageyama S; Hiraoka A; Omoto E; Akiyama H; Tsubaki K; Saito K; Kuriyama K; Oh H; Kitano K; Miyawaki S; Takeyama U; Yamada O; Nishikawa K; Takahashi M; Matsuda S; Ohtake H; Ohno R
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S65-71. PubMed ID: 11587370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superiority of anthracycline-free treatment in standard-risk acute promyelocytic leukemia: A systematic review and comparative epidemiological analysis.
    Langdon K; Cosentino S; Wawryk O
    Cancer Rep (Hoboken); 2024 Mar; 7(3):e2035. PubMed ID: 38507294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
    Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
    Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of arsenic trioxide on the treatment of children with newly diagnosed acute promyelocytic leukemia in China.
    Zhang L; Zhu X; Zou Y; Chen Y; Chen X
    Int J Hematol; 2011 Feb; 93(2):199-205. PubMed ID: 21287409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance).
    Kutny MA; Geyer S; Laumann KM; Gregory J; Willman CL; Stock W; Larson RA; Powell BL; Feusner JH
    Pediatr Blood Cancer; 2019 Mar; 66(3):e27542. PubMed ID: 30393935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group.
    Kanamaru A; Takemoto Y; Tanimoto M; Murakami H; Asou N; Kobayashi T; Kuriyama K; Ohmoto E; Sakamaki H; Tsubaki K
    Blood; 1995 Mar; 85(5):1202-6. PubMed ID: 7858250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group.
    De Botton S; Dombret H; Sanz M; Miguel JS; Caillot D; Zittoun R; Gardembas M; Stamatoulas A; Condé E; Guerci A; Gardin C; Geiser K; Makhoul DC; Reman O; de la Serna J; Lefrere F; Chomienne C; Chastang C; Degos L; Fenaux P
    Blood; 1998 Oct; 92(8):2712-8. PubMed ID: 9763554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term survey of outcome in acute promyelocytic leukemia.
    Hu J; Shen Z; Sun H; Wu W; Li X; Sun G; Wang Z
    Chin Med J (Engl); 2000 Feb; 113(2):107-10. PubMed ID: 11775530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation syndrome and coagulation disorder - comparison between treatment with oral and intravenous arsenics in pediatric acute promyelocytic leukemia.
    Luo JS; Zhang XL; Huang DP; Chen YQ; Wan WQ; Mai HR; Chen HQ; Wen H; Liu RY; Chen GH; Li Y; Luo XQ; Tang YL; Huang LB
    Ann Hematol; 2023 Jul; 102(7):1713-1721. PubMed ID: 37199788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.
    Kayser S; Krzykalla J; Elliott MA; Norsworthy K; Gonzales P; Hills RK; Baer MR; Ráčil Z; Mayer J; Novak J; Žák P; Szotkowski T; Grimwade D; Russell NH; Walter RB; Estey EH; Westermann J; Görner M; Benner A; Krämer A; Smith BD; Burnett AK; Thiede C; Röllig C; Ho AD; Ehninger G; Schlenk RF; Tallman MS; Levis MJ; Platzbecker U
    Leukemia; 2017 Nov; 31(11):2347-2354. PubMed ID: 28322237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
    Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
    Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.